TITLE

UK Vioxx litigation splits up into US and UK class actions

AUTHOR(S)
Harris, Joanne
PUB. DATE
September 2005
SOURCE
Lawyer;9/5/2005, Vol. 19 Issue 34, p10
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that British law firms are preparing to fight arthritis drug company Merck after the first successful lawsuit against it for its drug Vioxx which had been found to increase the risk of cardiovascular disease. Actual and punitive damages awarded to Carol Ernst, the widow of a Vioxx patient; Mark Lanier, the Texan lawyer, who represented Ernst, still with another 2,000 clients seeking compensation; Obstacles to be overcome before claimants can pick up compensation.
ACCESSION #
18238893

 

Related Articles

  • Merck scores victory in three Vioxx appeals.  // Nature;6/5/2008, Vol. 453 Issue 7196, p710 

    The article reports on the ruling of a three-judge panel in the appeals court in Texas regarding the public painkiller Vioxx lawsuit of Merck & Co. Inc. It states that the panel reversed a $26-million jury verdict and said that the lawyers for plaintiff Carol Ernst had failed to prove that the...

  • Vioxx award good news for Canadian lawsuits. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;9/27/2005, Vol. 173 Issue 7, p744 

    Reports on the Texas court ruling in favor of Carol Ernst, who sued the drug manufacturer Merck & Co. after her husband died of an arrhythmia after taking rofecoxib, as of September 2005. Facts of the case; Overview of the drug; Implications for similar lawsuits in Canada.

  • THE VIOXX SCORECARD.  // Medical Marketing & Media;Jan2007, Vol. 42 Issue 1, p37 

    The article presents several court cases filed against Merck and Co. in the U.S. by various Americans related to the use of the firm's drug Vioxx. This drug is being used for pain relief and was being studied for its ability to prevent cancer and block the growth of new blood vessels to solid...

  • Battle over Fosamax bursts into court. Moynihan, Ray // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/8/2009, Vol. 339 Issue 7716, p320 

    The article focuses on the controversy surrounding the pharmaceutical company Merck regarding its golden goose alendronic acid drug Fosamax. An estimated 800 plaintiffs allege that Merck's alendronic acid drug caused them to suffer osteonecrosis of the jaw or the dead jaw syndrome. However, the...

  • Plaintiffs Gear Up For Vioxx Class Action. Melnitzer, Julius // Corporate Legal Times;Oct2005, Vol. 15 Issue 167, p60 

    Reports on the class action lawsuit facing Merck & Co. New Jersey Superior Court Judge Carol Higbee's certification of a national class that includes every health maintenance plan and insurance company that let its participants buy Vioxx; Merck's loss in a lawsuit filed in Texas.

  • Sleepless Nights? Barrett, Jennifer // Newsweek (Pacific Edition);8/29/2005 (Pacific Edition), Vol. 146 Issue 9, p6 

    Looks at the effect a recent judgment won by Carol Ernst will have on the defendant, pharmaceutical company Merck. Description of the decision that linked the drug Vioxx to the death of Ernst's husband; How Merck will cope with the 4,200 pending lawsuits against it; Comments from analyst Albert...

  • Is Merck Winning or Losing in the Vioxx Trials? Simons, John // Fortune;5/15/2006, Vol. 153 Issue 9, p28 

    This article discusses the lawsuit over Merck & Co. Inc.'s anti-inflammatory drug Vioxx, which consumers are claiming causes cardiovascular damage. Over 11,500 lawsuit cases have been filed against Merck & Co. Inc., including a $32 million judgment against them in Texas. The drug company plans...

  • Merck wins suit, keeps Singulair close to chest. P., Shankar // njbiz;8/24/2009, Vol. 22 Issue 34, p2 

    The article discusses a court case won by Merck & Co. in August 2009 against Teva Pharmaceuticals. Merck & Co. filed a $4.3 billion patent lawsuit after Teva allegedly tried to introduce a generic type of the asthma drug Singulair. It states the ruling will not apply to other pharmaceutical...

  • Sleepless Nights? Barrett, Jennifer // Newsweek (Atlantic Edition);8/29/2005 (Atlantic Edition), Vol. 146 Issue 9, p6 

    Looks at the effect a recent judgment won by Carol Ernst will have on the defendant, pharmaceutical company Merck. Description of the decision that linked the drug Vioxx to the death of Ernst's husband; How Merck will cope with the 4,200 pending lawsuits against it; Comments from analyst Albert...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics